Literature DB >> 18942611

Thromboembolic prophylaxis in blunt traumatic intracranial hemorrhage: a retrospective review.

Aron J Depew1, Charles K Hu, Andre C Nguyen, Natalie Driessen.   

Abstract

There are few data in the literature on venous thromboembolic (VTE) prophylaxis for the traumatic population with intracranial hemorrhage (ICH). We reviewed our institutional experience and compared the incidence of deep vein thrombosis and pulmonary embolism in patients with ICH receiving either early prophylaxis (< 72 hours from admission) or late prophylaxis (> 72 hours from admission), and the respective incidences in progression of intracranial hemorrhage. We identified 124 patients for this study. There were 29 patients (23%) who received early (< 72 hours) pharmacological VTE prophylaxis and 53 patients (43%) received late (> 72 hours) prophylaxis. In the study, 42 patients had intermittent pneumatic compression devices and received no pharmacological VTE prophylaxis. Among those with pharmacological VTE prophylaxis, 10 patients (8%) developed VTE (9 deep vein thrombosis and 1 pulmonary embolism). Three patients with pharmacological VTE prophylaxis developed ICH progression, with one being clinically significant. Our institutional review demonstrated that it seems safe to initiate early pharmacological VTE prophylaxis in blunt head trauma with stable ICH. Nevertheless, further prospective randomized studies are needed to fully elucidate the safety and efficacy in the timing of prophylaxis for blunt head trauma with ICH.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18942611

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  7 in total

1.  Safety of Chemical DVT Prophylaxis in Severe Traumatic Brain Injury with Invasive Monitoring Devices.

Authors:  Bradley A Dengler; Paolo Mendez-Gomez; Amanda Chavez; Lacey Avila; Joel Michalek; Brian Hernandez; Ramesh Grandhi; Ali Seifi
Journal:  Neurocrit Care       Date:  2016-10       Impact factor: 3.210

2.  The Role of Chemoprophylactic Agents in Modulating Platelet Aggregability After Traumatic Brain Injury.

Authors:  Mackenzie C Morris; Farzaan Kassam; Aron Bercz; Nadine Beckmann; Fabian Schumacher; Erich Gulbins; Amy T Makley; Michael D Goodman
Journal:  J Surg Res       Date:  2019-07-03       Impact factor: 2.192

Review 3.  Pharmacologic venous thromboembolism prophylaxis after traumatic brain injury: a critical literature review.

Authors:  Herb A Phelan
Journal:  J Neurotrauma       Date:  2012-07-01       Impact factor: 5.269

Review 4.  A Systematic Review of the Benefits and Risks of Anticoagulation Following Traumatic Brain Injury.

Authors:  Xian Shen; Sarah K Dutcher; Jacqueline Palmer; Xinggang Liu; Zippora Kiptanui; Bilal Khokhar; Mohammad H Al-Jawadi; Yue Zhu; Ilene H Zuckerman
Journal:  J Head Trauma Rehabil       Date:  2015 Jul-Aug       Impact factor: 2.710

5.  The Parkland Protocol's modified Berne-Norwood criteria predict two tiers of risk for traumatic brain injury progression.

Authors:  Rachel A Pastorek; Michael W Cripps; Ira H Bernstein; William W Scott; Christopher J Madden; Kim L Rickert; Steven E Wolf; Herb A Phelan
Journal:  J Neurotrauma       Date:  2014-08-28       Impact factor: 5.269

Review 6.  Timing for deep vein thrombosis chemoprophylaxis in traumatic brain injury: an evidence-based review.

Authors:  Hiba Abdel-Aziz; C Michael Dunham; Rema J Malik; Barbara M Hileman
Journal:  Crit Care       Date:  2015-03-24       Impact factor: 9.097

7.  Venous thromboembolism prophylaxis in patients with traumatic brain injury: a systematic review.

Authors:  Yohalakshmi Chelladurai; Kent A Stevens; Elliott R Haut; Daniel J Brotman; Ritu Sharma; Kenneth M Shermock; Sosena Kebede; Sonal Singh; Jodi B Segal
Journal:  F1000Res       Date:  2013-05-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.